Concepedia

Megan Parsi

MP

Statistics

Publications

2

Citations

52

H-Index

2

Active since

2022

Affiliations

Advaxis (United States)(Current)

Megan Parsi is an author at Advaxis (United States) specializing in tumor immunity, t cell immunity, and immune regulation.

Top concepts

Publications per year

2022–2022

2

Publications

2

ADXS31142 Immunotherapy ± Pembrolizumab Treatment for Metastatic Castration-Resistant Prostate Cancer: Open-Label Phase I/II KEYNOTE-046 Study

Mark N. Stein, Lawrence Fong, Ronald Tutrone et al. · The Oncologist · 2022 · 38 citations · Full text

A phase 2 study of an off-the-shelf, multi-neoantigen vector (ADXS-503) in patients with metastatic non–small cell lung cancer either progressing on prior pembrolizumab or in the first-line setting.

Gregory J. Gerstner, Suresh S. Ramalingam, Aaron Lisberg et al. · Journal of Clinical Oncology · 2022 · 14 citations

, , +24

1–2 of 2